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Serum malondialdehyde and prevalent cardiovascular disease receptor uptake of oxidized low-density lipoprotein
in hemodialysis. (LDL), a process ultimately leading to foam cell forma-
Background. Oxidative stress has been proposed as a mech- tion [6–8]; the promotion of arterial macrophage accu-anism by which the accelerated rate of cardiovascular disease
mulation via a chemotactic effect on monocytes and the(CVD) observed in maintenance hemodialysis (HD) patients
inhibition of macrophage migration [9, 10] is apparentlymay be explained. This study examined the effects of HD and
CVD on serum malondialdehyde (MDA) levels as a marker through the induction of monocyte chemotactic protein-1
of oxidative stress in HD patients with and without prevalent [11]. Furthermore, it has been proposed that oxidized
CVD. Serum MDA levels and CVD prevalence in HD were LDL may stimulate intimal monocytes to differentiatemodeled.
into resident macrophages [12]. Endothelial adhesive-Methods. Serum MDA was determined using spectropho-
ness may be increased by oxidation-induced leukocytetometry in HD patients (N 5 76, 53 men and 23 women, mean
age 63.8 years) immediately prior to and at the conclusion of adhesion molecules on monocytes [13]. Additionally, ox-
one midweek HD treatment. Traditional CVD risk factors, idative damage may promote atherosclerosis through
including serum lipids, lipoproteins, apolipoproteins, and fi- cytotoxicity, a process associated with endothelial cell
brinogen, were also measured, as were serum chemistry and
damage [14, 15]. The inhibition of vasorelaxation is bydialysis adequacy.
impaired endothelium-derived relaxation factor [16] andResults. Mean serum MDA levels were significantly elevated
in HD patients with prevalent CVD compared with those with- tissue factor synthesis [17].
out, whereas serum lipoprotein and plasma fibrinogen levels Nonenzymatic lipid peroxidation is one free radical-
did not differ between the two groups. Patients in the highest associated process through which oxidative stress pro-
compared with the lowest tertile of postdialysis MDA were
motes cellular damage. Serum malondialdehyde (MDA)nearly four times as likely to have prevalent CVD, and serum
is the breakdown product of the major chain reactionsMDA was the single strongest predictor of prevalent CVD in
this patient population. leading to definite oxidation of polyunsaturated fatty
Conclusions. These findings indicate the presence of oxida- acids such as linoleic and linolenic acid (n6 series) and
tive stress in HD patients, and are consistent with the theory thus serves as a reliable marker of oxidative stress
of oxidative stress as a factor in accelerated CVD in this popula-
[18, 19].tion.
It has been noted that serum or plasma MDA is ele-
vated in various disease states, including the period im-
mediately following an acute myocardial infarction (MI)Compelling evidence now exists linking oxidative
[20]. Serum MDA levels have also been shown to bestress and the pathogenesis and progression of athero-
elevated in maintenance hemodialysis (HD) patientssclerosis [1–5]. Mechanisms through which this associa-
[21], a population with an accelerated cardiovasculartion may be explained include: macrophage scavenger
morbidity and cardiac mortality rate [22–24]. Additional
evidence of oxidative stress in HD patients can be found
in the increased susceptibility of LDL cholesterol to per-Key words: dialysis, oxidative stress, maintenance hemodialysis, ath-
erosclerosis, lipid peroxidation, CVD. oxidation, as measured by decreased in vitro lag time
[25–31]. Although Schettler et al found no evidence thatReceived for publication February 11, 1998
dialysis itself caused lipid hydroperoxide formation, theyand in revised form March 23, 1999
Accepted for publication March 26, 1999 concluded that HD patients were nevertheless in a state
of oxidative stress and that the elevated plasma TBARS 1999 by the International Society of Nephrology
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seen in HD patients compared with healthy controls cose, using the glucose oxidase-peroxidase aminophena-
zone phenol (GOD-PAP) enzymatic colorimetric test;resulted from something other than the dialysis treat-
ment [32]. The existence of a stable, oxidizing component phosphorus, using the molybdate reaction; creatinine,
using the picric acid technique; serum urea, enzymati-has been identified in the plasma of uremic patients, and
this endogenous oxidizing agent could not be inhibited cally determined using reagent from Sigma (St. Louis,
MO, USA); potassium, calcium, and uric acid.by physiological concentrations of vitamin C, vitamin E,
or reduced glutathione [33].
Serum malondialdehydeThe purpose of this study was to examine potential
determinants of serum MDA, a marker of oxidative To determine serum MDA concentrations, 5 ml of
blood were collected from individuals immediately priorstress in HD patients. Serum MDA levels immediately
prior to and immediately after one midweek HD treat- to their midweek HD treatment into an empty test tube.
An additional sample of 5 ml blood was drawn immedi-ment were modeled using linear regression analysis.
Prevalent cardiovascular disease (CVD) in maintenance ately at the end of the HD treatment. After centrifuga-
tion at 1500 g for 10 minutes at 48C, the serum wasHD patients was also modeled.
removed for MDA determination. This was carried
out spectrophotometrically with 2-thiobarbituric acid
METHODS
(TBA) solution as described by Bird and Draper [34].
Study population The concentration of lipid peroxides in plasma was ex-
pressed with 1,1,2,2,-tetramethoxypropane as the stan-In this clinic-based cross-sectional study, 76 adult
maintenance HD patients were randomly selected from dard (nmol/ml).
the entire adult HD population of the Department of
Serum lipids, apolipoproteins, and plasma fibrinogenNephrology, E. Wolfson Medical Center, Holon, Israel.
Patients defined as having prevalent CVD (N 5 44) Total cholesterol (TC) was determined using the enzy-
matic cholesterol oxidase-peroxidase aminophenazoneincluded those with a documented history of myocardial
infarction (MI), stroke (ischemic only), coronary revas- phenol (CHOD-PAP) colorimetric test. High-density li-
poprotein cholesterol was precipitated with phospho-cularization procedures (CABG, PTCA), angina pecto-
ris, transient cerebral ischemia (TIA), peripheral artery tungstic acid and magnesium chloride followed by centri-
fugation, with the supernatant tested via colorimetry,surgery (not including the A-V fistula), carotid endarter-
ectomy, and peripheral vascular disease. The presence and triglycerides were measured using the glycerol
phosphate oxidase-peroxidase aminophenazone phenolin the patient medical record of hospitalization and/or
treatment for one or more of the aforementioned condi- (GPO-PAP) enzymatic colorimetric test (all Boehringer-
Mannheim products). Low density lipoprotein (LDL)tions was followed by the location of supporting diagnos-
tic criteria, including electrocardiographic, angiographic, cholesterol was calculated using the Friedewald equation
[35]. Quality control was observed by including Boeh-biochemical (enzyme alterations), and surgery dates. The
remaining 32 patients had no clinically evident CVD ringer-Mannheim’s Precinorm U-Universal Control Se-
rum L for each batch tested for lipids and regular chemis-documented in the medical record.
All patients had received a minimum of 12 hours per try. Manitrol (Baxter, Columbia, MD, USA) and the
Murex Diagnostics Quality Assessment Kit were alsoweek of maintenance HD therapy (three treatments of
four hours each) for a minimum of three months prior used with each batch tested. Plasma fibrinogen was col-
lected separately in test tubes prepared with sodium ci-to the study onset. Dialysis was carried out in all cases
on AK100 dialyzers by Gambro using Nipro Sureflux trate solution (0.11 mol/liter) at a ratio of nine parts
freshly drawn blood to one part sodium citrate solution.cellulose triacetate hollow fiber dialyzer filters sized 1.1
m2 (N 5 59) or 1.5 m2 (N 5 17). The Fibrinogen Kinetic kit (Boehringer-Mannheim)
with the Precimat Chromogen standard was used, andParticipants had no known history of malignancy (ex-
cept nonmelanoma skin cancer), were not insulin depen- PreciChrom I/II was used for quality control. Apolipo-
proteins A-1 and B were measured using Tinaquant kitsdent, and had no active liver disease.
for apo-A1 and apo-B, respectively (Boehringer-Mann-
Blood chemistry heim) and analyzed on a Hitachi 704 autoanalyzer.
Fasting (14 hr) blood was drawn into vacutainer tubes
Measurement of hemodialysis adequacywith no additive for chemistry analysis. Serum was sepa-
rated via centrifugation within two hours of being drawn. The delivered dose of HD was described as the frac-
tional clearance of urea as a function of its distributionThe following determinations were made on the same
day, according to standard protocol at the Biochemistry volume (Kt/V) and was determined using the Kt/V natu-
ral logarithm formula [36]. The slow-flow sampling tech-Laboratory at E. Wolfson Medical Center using Boeh-
ringer-Mannheim (Mannheim, Germany) products: glu- nique was used whereby the blood pump was slowed to
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Table 1. Characteristics of hemodialysis population by history of50 ml/min, and after 50 seconds had elapsed, blood was
cardiovascular disease (CVD)
drawn from the arterial sampling port closest to the pa-
History of No CVDtient.
CVD history
Variable Mean sd Mean sdStatistical analysis
Age years 62.7 14.3 65.4 14.3Data were stored on spreadsheet using Microsoft Ex-
Years hemodialysis 4.9 4.9 3.4 4.9cel 5.0 software with Hebrew language support (Micro-
Kt/V 1.4 0.3 1.4 0.4
soft Corporation, 1985–1994). Analysis of data was carried MDA pre-treatmenta nmol/ml 2.8 0.6 2.4 0.4
MDA2 post-treatmenta nmol/ml 2.3 0.4 1.9 0.2out using Statistix Analytic Software, 1992. Descriptive
Creatinine mg/dl 8.3 1.6 8.4 1.5statistics, including central tendency measures, range,
Urea pre-treatment mg/dl 143.1 37.1 162.9 62.1
and standard deviation, were obtained for each variable. Glucose mg/dl 123.4 45.8 109.9 61.1
Phosphorus mg/dl 6.2 1.8 6.2 1.9Pearson’s correlation coefficients were calculated for
Calcium mg/dl 8.9 1.9 9.4 0.7MDA and numeric variables, whereas Spearman’s rho
Uric acid mg/dl 5.7 1.6 5.6 1.7
was used to test associations between MDA and nominal Albumin mg/dl 4.2 0.4 4.1 0.3
Potassium mg/dl 4.97 0.8 5.1 0.8variables in univariate analysis. The significance of cor-
Total cholesterol mg/dl 167.2 47.1 161.4 30.5relations was calculated using least-squares linear-
LDL mg/dl 105.7 36.9 103.5 20.5
regression analysis. Because of the strong multicollinearity HDL mg/dl 35.8 7.9 35.5 13.6
Triglycerides mg/dl 128.1 58.2 126.8 77.6of serum lipoproteins and apolipoproteins, analysis of
ApoA mg/dl 94.8 15.7 96.4 13.1principal components was used to create a pattern vari-
ApoB mg/dl 73.1 21.6 73.2 10.6
able reflecting these parameters. The principal compo- Fibrinogen mg/dl 354.8 142.8 352.8 96.9
SBP pre-treatment mm Hg 151.1 26.8 145.6 17.1nent was used in both univariate and multivariate analy-
DBP pre-treatment mm Hg 81.1 13.2 85.1 9.1ses. Forward stepwise multiple linear regression analysis
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pres-was used to model serum MDA levels before and after
sure; sd, standard deviation.
the midweek HD treatment, wherein Student’s t-test was a P , 0.001
used to determine whether a regression coefficient was
significantly different from zero, and the F-test was used
to examine the hypothesis that the inclusion of a specific
lent CVD. Only the years of HD treatment (r 5 0.31,variable significantly improved the equation. Prevalent
P , 0.002) were significantly correlated to MDA1 in HDCVD in HD patients was modeled using logistic-regres-
patients without prevalent CVD. Post-treatment serumsion analysis. Here, a saturated model was developed,
MDA levels (MDA2) were found to be significantly posi-and a backward, stepwise approach was used to arrive
at the most parsimonious model. The Wald statistic was tively correlated with prevalent CVD (r 5 0.45, P ,
used to test whether a coefficient was significantly differ- 0.0005) and were significantly negatively correlated with
ent from zero, and chi square was used to determine apoA (r 5 20.34, P , 0.02) and serum albumin (r 5
whether the inclusion of a variable significantly improved 0.32, P , 0.02). These correlations were significant only
the predictability of the equation. Odds ratios were cal- in HD patients with prevalent CVD.
culated, and the predictability of the equation was deter- In multivariate analysis of serum MDA1, the following
mined. All tests were considered significant at P , 0.05. variables entered into the equation: plasma fibrinogen,
total serum cholesterol (TC), number of years of HD
treatment, and prevalent CVD (entered into the equa-RESULTS
tion as the dummy variable, 1 5 prevalent CVD, 0 5Table 1 describes study population characteristics by
no prevalent CVD). The final model was as follows:CVD prevalence. As can be seen, HD patients did not
MDA1 5 2.6 1 [0.4 (CVD)] 1 [0.001 (plasma fibrino-differ by CVD status on any parameter measured except
gen)] 1 [0.03 (years of HD treatment)] 2 [0.004 (serumserum MDA, both before and after the midweek HD
TC). This model accounts for approximately 41% of thetreatment.
variation in pretreatment MDA levels in HD patientsIn univariate analysis of serum MDA levels in HD
(r 5 0.641, P , 0.001). When LDL was substituted forpatients, pretreatment serum MDA levels (MDA1) were
TC in this model, no difference in predictability wasfound to be significantly positively associated with preva-
achieved, and again, the final model accounted for ap-lent CVD (r 5 0.47, P , 0.0002) and years of HD treat-
proximately 41% of the variation in MDA1 levelsment (r 5 0.29, P , 0.001), and were significantly nega-
(r 5 0.64, P , 0.001). Finally, the principal componenttively correlated with apoA (r 5 20.32, P , 0.01), serum
generated by TC and LDL, called PC1, was substitutedLDL (r 5 20.29, P , 0.02), and serum TC (r 5 20.31,
for TC or LDL entered individually into the model.P , 0.03). Stratifying for CVD prevalence revealed that
these associations remained significant in HD with preva- PC1 did not improve the equation, which accounted for
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approximately 41% of variation in MDA1 (r 5 0.64, The implication of a role for acute phase reactants in
the inverse association between apoA and MDA mayP , 0.001).
When post-treatment MDA was modeled (MDA2), also apply to the significant, inverse correlation observed
between serum LDL and TC and MDA immediatelyapolipoprotein A (apoA) and CVD entered the equation
so that MDA2 5 2.7 2 [0.007 (apoA)] 1 [0.35 (CVD), prior to the midweek HD treatment. Significant inverse
correlations between serum LDL as well as TC and acuter 5 0.51, P , 0.0003], accounting for nearly 28% of the
variation in post-treatment MDA. Alternatively, serum phase proteins in other disease states have been reported
[39]. A possible mechanism might include increased up-albumin (alb) could be entered into the equation in place
of apoA so that the final equation was MDA2 5 3.3 2 take of LDL by oxidized macrophages via the oxidized
LDL receptor. Observed in vitro, this effect might be[0.32 (alb)] 1 [0.35 (CVD), r 5 52, P , 0.0004], account-
ing for approximately 27% of the variation in MDA2. attributable to an increased number of LDL receptors
on the surface of oxidized macrophages [42].In univariate analyses of prevalent CVD in HD pa-
tients, serum MDA1 (OR 5 8.37, 95% CI, 2.44 to 28.66, The significant inverse correlation between postdial-
ysis MDA and serum albumin levels may reflect the sameP 5 0.0007) and MDA2 (OR 5 21.52, 95% CI, 2.95 to
157.07, P 5 0.0024) were both found to contribute to the mechanism underlying the association observed between
acute-phase proteins and serum albumin [43]. A commonexplanation of variation in CVD prevalence. Logistic-
regression analysis was also used to develop odds ratios event, which could be chronic HD treatment, might lead
to the elevation of acute-phase proteins, includingfor tertiles of MDA1 and MDA2. The odds ratio for
CVD in the highest versus the lowest tertile of MDA1 C-reactive protein (CRP) and serum amyloid A (SAA),
as well as to the elevation of serum MDA. Both CRP andwas 2.71 (95% CI, 1.42 to 5.19). Using MDA2 as the
predictor variable, the odds ratio for CVD in the highest SAA have been shown to be significantly and positively
associated with number of years of dialysis treatmentversus the lowest tertile was 3.65 (95% CI, 1.60 to 8.32).
When backward, stepwise logistic regression was used [41], and this study found a significantly positive correla-
tion between the years of HD treatment and serumto develop a multiple regression analysis of prevalent
MDA in multivariate analysis.CVD in HD patients, only MDA1 or MDA2 remained
That serum MDA is positively associated with preva-in the model.
lent CVD in HD patients suggests that HD patients
in greater oxidative stress are at greater risk of CVD.
DISCUSSION Alternatively, the presence of CVD may present an
In HD patients with prevalent CVD, a significant in- added oxidative burden or may somehow be associated
verse correlation between apoA and both pre- and post- with alterations in other factors, such as acute-phase
treatment MDA levels was observed in univariate analy- proteins, associated with oxidative stress. Because of the
sis. This observation may reflect antioxidant qualities cross-sectional study design, an assignment of causality
attributed to apoA. In vitro, gramoxone-induced oxida- cannot be made.
tion of HepG2 cells led to a twofold decrease in apoA When modeled using logistic regression analysis, prev-
mRNA and a fourfold increase in the rate of apoA alent CVD in HD patients was best predicted by MDA
mRNA degradation, creating an inverse association be- only. Other traditional risk factors for CVD, including
tween oxidative stress and apoA [37]. On the other hand, TC, HDL, LDL, triglycerides, fibrinogen, or the presence
serum apoA levels were not significantly different be- of diabetes, did not enter into the equation nor were
tween HD patients with and without prevalent CVD. their levels different in HD patients with or without
The inverse association between apoA and MDA may prevalent CVD.
therefore reflect less efficiency of antioxidant activity in The identification of MDA as a predictor of CVD in
the apoA of HD patients with CVD. This concept is HD patients may underscore the role of oxidative stress
analogous to that described by Maggi et al, whereby as a cardiac risk factor in this patient population.
LDL vitamin E levels were shown to be less efficient, Whether exacerbated by the dialysis treatment itself
although present in the same amounts, in HD patients (loss of antioxidants into the dialysate, exposure of blood
compared with healthy controls [31]. In other disease to the dialysis circuit, etc.) contributed to by some factor
states, apoA levels have been observed to be inversely in uremic plasma or because of alterations in the effi-
correlated with acute phase reactants [38, 39], and mark- ciency of antioxidants [30–31, 33], it can be concluded
ers of oxidative stress have been shown to be elevated that HD patients are in oxidative stress as measured by
in acute phase reactions [40]. Acute-phase proteins have serum MDA. To establish oxidative stress as a causative
also been shown to be elevated in HD patients compared factor in CVD in HD patients, however, a prospective
with controls [41]. Whether or not acute-phase proteins study or, alternatively, a clinical trial in which antioxi-
are higher in HD patients with prevalent CVD compared dants could be used to reduce oxidative stress in this
group is required.with those without it is a topic for further study.
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